Kindly find the enclosed herewith the meeting updates of the Board of Directors Meeting of the Company held today under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.8 pts less than Nifty Microcap 250 and 8.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
BDH Industries' board met on 23rd May 2025 and approved audited standalone results for Q4 and FY ended 31st March 2025, with statutory auditor CLB & Associates issuing an unmodified (clean) opinion. Full-year revenue from operations fell about 22.5% to Rs. 6,650.83 lakhs (from Rs. 8,583.10 lakhs last year), while profit after tax eased roughly 6% to Rs. 927.33 lakhs (from Rs. 986.78 lakhs) and EPS came in at Rs. 16.11 vs Rs. 17.14. Despite the topline dip, operating profit margins expanded and net cash from operations swung sharply positive to Rs. 1,477 lakhs (from negative Rs. 187 lakhs), supported by lower borrowings (Rs. 98 lakhs vs Rs. 869 lakhs) and strong cash balance of Rs. 3,116 lakhs. The board recommended a dividend of Rs. 4.50 per share (face value Rs. 10), scheduled the 35th AGM for 8th August 2025, and approved re-appointment of Ms. Jayashree Nair as Managing Director along with the re-designation and re-appointment of Mr. S.C. Kachhara as Managing Director. New internal, cost and secretarial auditors were also appointed for FY26 onwards.
Mixed signals for shareholders: revenue declined sharply and PAT dipped modestly, but margins expanded, the balance sheet strengthened with near-zero debt and higher cash, and a steady dividend (Rs. 4.50/share) was declared. Overall a stable, cash-rich outcome despite the topline contraction, with management continuity at the top.